Ekso Bionics Teams Up with Performance Contracting, Inc. for Innovative Testing Approach of EVO™ Technology

Ekso Bionics Holdings today announced that Performance Contracting, Inc. (“PCI”), a leading U.S. specialty contractor, is the latest company in the construction vertical to implement field testing of EVO™ exoskeleton vests.

Over the course of a year, PCI employees in six Bay Area counties have committed to testing EVO™ exoskeleton vests for the Company’s continued product development and innovation.

“We are excited that PCI’s workforce will benefit from our novel EVO technology,” commented Michael Pratt, Vice President of Ekso Bionics. “Companies within the construction vertical are starting to recognize that EVO provides meaningful support for workers when performing routine and labor-intensive tasks. We look forward to supporting our growing user base, including PCI, with our unique solution and driving increased adoption with our flexible subscription-based offering.”

EVO is the world’s most durable, naturally-tracking, and assistive exoskeleton vest. The exoskeleton offers unique benefits in the construction industry that aids workers when performing strenuous tasks in order to reduce fatigue and worker-related injuries while increasing productivity.

“Putting our people first has always been a key differentiator at PCI,” said David Link, Regional Manager, Bay Area of PCI. “With our team of over 6,300 skilled craft workers across the United States, it is imperative for us to invest in both their well-being and productivity to remain an industry leader. Ekso’s EVO aligns with our most important core value of safety and supports our performance-driven culture. We are eager to explore this technology in the field with the goal of helping our employees achieve their fullest potential.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.
“These study results are highly encouraging especially given the short treatment duration of 10 days with BX004,” said Jonathan Solomon, Chief Executive Officer of BiomX. “In Part 2 of the study, BX004 showed clinically meaningful improvement in pulmonary function compared to placebo, as measured by relative FEV11 improvement (5.67% at Day 17, 1 week after end of treatment) and Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain (8.87 points at Day 17) in a predefined subgroup of patients with reduced lung function.”  
Importantly, the study reported no serious treatment-related adverse events from any of the 109 patients treated with InGeneron’s Transpose® RT cell therapy system.

By using this website you agree to accept Medical Device News Magazine Privacy Policy